Umecrine Cognition Ab

Index Pharmaceuticals Ab

Paul Alhadeff

Thomas Meijer

Magnus Doverskog

Maja Johansson

Nicolaas Schipper

Peter Zerhouni

Graeme William Andrew Hamilton Johnston

Christine Dieterich Johansson

Wei Tian

Britta Dathe

Pernilla Helena Sandwall

Ralf Wanner

Franziska Müller Corona

The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.

Formulation

The present invention is directed to a novel pharmaceutical formulation comprising 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.

Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

The present invention is directed to a novel pharmaceutical formulation comprising 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.

Pharmaceutical formulation of 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime

Growing community of inventors

Uttran, Sweden

Paul Alhadeff